Aqueous humour interleukin-6 and vision outcomes with anti-vascular endothelial growth factor therapy
Yasir Jamal Sepah,Diana V. Do,Marina Mesquida,Bann-Mo Day,Steven Blotner,Rubbia Afridi,Muhammad Sohail Halim,Kyu Hong,Eric Wakshull,Sascha Fauser,Ivaylo Stoilov,Quan Dong Nguyen,P. Abraham,D. V. Alfaro,A. Antoszyk,M. Antworth,B. Baker,C. Baker,M. Balles,D. Boyer,W. Bridges,D. M. Brown,B. Busbee,M. Busquets,C. Chan,N. Chaudhry,S. Chen,J. Christoforidis,T. Ciulla,W. L. Clark,T. Cleland,T. Connor,A. Daccache,A. Dessouki,K. Diddie,B. Doft,R. Dreyer,D. W. Faber,L. Feiner,R. Feldman,P. Ferrone,G. Fox,S. Foxman,R. Frenkel,A. Fung,R. Gallemore,T. Ghuman,V. Gonzalez,A. Gordon,C. Gordon,S. Gupta,S. Hariprasad,J. Heier,A. Ho,D. Holmes,J. Huang,J. P. Hubschman,H. Hudson,D. Ie,R. Johnson,R. Katz,S. Kiss,J. Kitchens,G. Kokame,E. Lit,M. Liu,J. K. Luu,M. MacCumber,S. Madreperla,D. Marcus,A. Martidis,J. Martinez,M. Michels,D. Miller,L. Morse,M. Nasir,Q. Nguyen,S. Oliver,K. Olsen,S. Patel,P. Pavan,J. Pearlman,J. Prenner,C. Regillo,E. Reichel,R. Rosa,S. Rose,S. Sadda,M. Samuel,L. Singerman,M. Singer,R. Singh,G. Stoller,I. Suner,A. Tabassian,B. Taney,A. Thach,M. Thomas,M. Tolentino,D. Tom,P. Tornambe,R. Torti,S. Truong,T. Verstraeten,A. Wagner,K. Wald,P. Weber,P. Weishaar,M. Wieland,D. Williams,T. Wong,M. Wood,J. Wroblewski,K. Zhang,D. V. Do,E. Lit,E. Kruger,J. Pollack,L. Halperin,M. Bennett,D. Boyer,D. Callanan,K. Zhang,A. Symons,P. Abraham,on behalf of the HARBOR,READ-3 Investigators
DOI: https://doi.org/10.1038/s41433-024-03015-2
IF: 4.4563
2024-04-16
Eye
Abstract:This analysis evaluated aqueous humour (AH) interleukin (IL)-6 concentrations and the association between AH IL-6 and visual outcomes in patients with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) receiving anti–vascular endothelial growth factor (VEGF) monotherapy.
ophthalmology